Cargando…

ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study

ABSTRACT: BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) and two stage hepatectomy with inter-stage portal vein embolization (TSH/PVE) are surgical maneuvers applied in patients with advanced malignancies considered unresectable by means of convention...

Descripción completa

Detalles Bibliográficos
Autores principales: Bednarsch, Jan, Czigany, Zoltan, Sharmeen, Samara, van der Kroft, Gregory, Strnad, Pavel, Ulmer, Tom Florian, Isfort, Peter, Bruners, Philipp, Lurje, Georg, Neumann, Ulf Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315489/
https://www.ncbi.nlm.nih.gov/pubmed/32580729
http://dx.doi.org/10.1186/s12957-020-01919-3
_version_ 1783550263308582912
author Bednarsch, Jan
Czigany, Zoltan
Sharmeen, Samara
van der Kroft, Gregory
Strnad, Pavel
Ulmer, Tom Florian
Isfort, Peter
Bruners, Philipp
Lurje, Georg
Neumann, Ulf Peter
author_facet Bednarsch, Jan
Czigany, Zoltan
Sharmeen, Samara
van der Kroft, Gregory
Strnad, Pavel
Ulmer, Tom Florian
Isfort, Peter
Bruners, Philipp
Lurje, Georg
Neumann, Ulf Peter
author_sort Bednarsch, Jan
collection PubMed
description ABSTRACT: BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) and two stage hepatectomy with inter-stage portal vein embolization (TSH/PVE) are surgical maneuvers applied in patients with advanced malignancies considered unresectable by means of conventional liver surgery. The aim of this report is to compare the oncologic outcome and technical feasibility of ALPPS and TSH/PVE in the scenario of colorectal liver metastases (CRLM). METHODS: All consecutive patients who underwent either ALPPS or TSH/PVE for CRLM between 2011 and 2017 in one hepatobiliary center were analyzed and compared regarding perioperative and long-term oncologic outcome. RESULTS: A cohort of 58 patients who underwent ALPPS (n = 21) or TSH/PVE (n = 37) was analyzed. The median overall survival (OS) was 28 months and 34 months after ALPPS and TSH/PVE (p = 0.963), respectively. The median recurrence-free survival (RFS) was higher following ALPPS with 19 months than following TSH/PVE with 10 months, but marginally failed to achieve statistical significance (p = 0.05). There were no differences in morbidity and mortality after stages 1 and 2. Patients undergoing ALPPS due to insufficient hypertrophy after TSH/PVE (rescue-ALPPS) displayed similar oncologic outcome as patients treated by conventional ALPPS or TSH/PVE (p = 0.971). CONCLUSIONS: ALPPS and TSH/PVE show excellent technical feasibility and comparable long-term oncologic outcome in CRLM. Rescue ALPPS appears to be a viable option for patients displaying insufficient hypertrophy after a TSH/PVE approach.
format Online
Article
Text
id pubmed-7315489
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73154892020-06-25 ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study Bednarsch, Jan Czigany, Zoltan Sharmeen, Samara van der Kroft, Gregory Strnad, Pavel Ulmer, Tom Florian Isfort, Peter Bruners, Philipp Lurje, Georg Neumann, Ulf Peter World J Surg Oncol Research ABSTRACT: BACKGROUND: Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) and two stage hepatectomy with inter-stage portal vein embolization (TSH/PVE) are surgical maneuvers applied in patients with advanced malignancies considered unresectable by means of conventional liver surgery. The aim of this report is to compare the oncologic outcome and technical feasibility of ALPPS and TSH/PVE in the scenario of colorectal liver metastases (CRLM). METHODS: All consecutive patients who underwent either ALPPS or TSH/PVE for CRLM between 2011 and 2017 in one hepatobiliary center were analyzed and compared regarding perioperative and long-term oncologic outcome. RESULTS: A cohort of 58 patients who underwent ALPPS (n = 21) or TSH/PVE (n = 37) was analyzed. The median overall survival (OS) was 28 months and 34 months after ALPPS and TSH/PVE (p = 0.963), respectively. The median recurrence-free survival (RFS) was higher following ALPPS with 19 months than following TSH/PVE with 10 months, but marginally failed to achieve statistical significance (p = 0.05). There were no differences in morbidity and mortality after stages 1 and 2. Patients undergoing ALPPS due to insufficient hypertrophy after TSH/PVE (rescue-ALPPS) displayed similar oncologic outcome as patients treated by conventional ALPPS or TSH/PVE (p = 0.971). CONCLUSIONS: ALPPS and TSH/PVE show excellent technical feasibility and comparable long-term oncologic outcome in CRLM. Rescue ALPPS appears to be a viable option for patients displaying insufficient hypertrophy after a TSH/PVE approach. BioMed Central 2020-06-24 /pmc/articles/PMC7315489/ /pubmed/32580729 http://dx.doi.org/10.1186/s12957-020-01919-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bednarsch, Jan
Czigany, Zoltan
Sharmeen, Samara
van der Kroft, Gregory
Strnad, Pavel
Ulmer, Tom Florian
Isfort, Peter
Bruners, Philipp
Lurje, Georg
Neumann, Ulf Peter
ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study
title ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study
title_full ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study
title_fullStr ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study
title_full_unstemmed ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study
title_short ALPPS versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study
title_sort alpps versus two-stage hepatectomy for colorectal liver metastases—–a comparative retrospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315489/
https://www.ncbi.nlm.nih.gov/pubmed/32580729
http://dx.doi.org/10.1186/s12957-020-01919-3
work_keys_str_mv AT bednarschjan alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy
AT cziganyzoltan alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy
AT sharmeensamara alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy
AT vanderkroftgregory alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy
AT strnadpavel alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy
AT ulmertomflorian alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy
AT isfortpeter alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy
AT brunersphilipp alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy
AT lurjegeorg alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy
AT neumannulfpeter alppsversustwostagehepatectomyforcolorectallivermetastasesacomparativeretrospectivecohortstudy